Pro­to­cols: Pri­vate eq­ui­ty buy-in val­ues in­Ven­tiv at $3.8B; Cel­gene de­nies char­i­ty scheme al­le­ga­tions

The CRO in­Ven­tiv Health has bagged a buy-in from Ad­vent Health that val­ues the com­pa­ny at $3.8 bil­lion. Ad­vent now be­comes a co-own­er of the com­pa­ny with Thomas H. Lee Part­ners and in­Ven­tiv will drop its plans for an IPO.

Seat­tle Ge­net­ics and its part­ner Take­da say they hit their pri­ma­ry end­point in a Phase III study of Ad­cetris for pa­tients with cu­ta­neous T-cell lym­phoma. The com­pa­nies called the da­ta “high­ly sta­tis­ti­cal­ly sig­nif­i­cant” in the rate of ob­jec­tive re­spons­es which last­ed at least four months. Seat­tle Ge­net­ics’ share price, though, bare­ly budged.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.